Filip Kos

Statistics

Publications

Citations

H-Index

Active since

2021

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

PathAI (United States)

Memorial Sloan Kettering Cancer Center

Moffitt Cancer Center

The Ohio State University

Filip Kos is an author at The University of Texas MD Anderson Cancer Center specializing in atezolizumab therapy, major pathologic response, and neoadjuvant therapy trials.

Publications per year

2021–2023

Publications

Artificial Intelligence–Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study

William D. Travis, Jennifer M. Giltnane, Filip Kos et al. · Journal of Thoracic Oncology · 2023 · 27 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Artificial intelligence (AI)–powered pathologic response (PathR) assessment of resection specimens after neoadjuvant atezolizumab in patients with non-small cell lung cancer: Results from the LCMC3 study.

William D. Travis, Jennifer M. Giltnane, John H. Abel et al. · Journal of Clinical Oncology · 2021 · 17 citations

Medicine, Oncology, Clinical Decision Support +16

1–2 of 2